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Of the five immunoglobulin isotypes, immunoglobulin G (IgG) is most abundant in human
serum.The four subclasses, IgG1, IgG2, IgG3, and IgG4, which are highly conserved, differ
in their constant region, particularly in their hinges and upper CH2 domains.These regions
are involved in binding to both IgG-Fc receptors (FcγR) and C1q. As a result, the different
subclasses have different effector functions, both in terms of triggering FcγR-expressing
cells, resulting in phagocytosis or antibody-dependent cell-mediated cytotoxicity, and acti-
vating complement. The Fc-regions also contain a binding epitope for the neonatal Fc
receptor (FcRn), responsible for the extended half-life, placental transport, and bidirectional
transport of IgG to mucosal surfaces. However, FcRn is also expressed in myeloid cells,
where it participates in both phagocytosis and antigen presentation together with classical
FcγR and complement. How these properties, IgG-polymorphisms and post-translational
modification of the antibodies in the form of glycosylation, affect IgG-function will be the
focus of the current review.
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INTRODUCTION
Immunoglobulin G (IgG) is one of the most abundant proteins
in human serum, accounting for about 10–20% of plasma pro-
tein. It is the major class of the five classes of immunoglobulins in
human beings, IgM, IgD, IgG, IgA, and IgE. These closely related
glycoproteins, composed of 82–96% protein and 4–18% carbo-
hydrate, differ in heavy chain structure and have different effector
functions. IgG can be further divided in four subclasses, named, in
order of decreasing abundance IgG1, IgG2, IgG3,and IgG4 (1). The
subclasses of IgG were discovered in the 1960s following extensive
studies using specific rabbit antisera against human IgG myeloma
proteins (1). Differences in structure and function of IgG sub-
classes are summarized in Table 1. Although they are more than
90% identical on the amino acid level, each subclass has a unique
profile with respect to antigen binding, immune complex forma-
tion, complement activation, triggering of effector cells, half-life,
and placental transport.
In addition, IgG antibody responses to different types of anti-
gens leads to marked skewing toward one of the subclasses. Selec-
tive subclass deficiencies are usually not detrimental to the indi-
vidual, but do sometimes lead to enhanced susceptibility toward
specific classes of pathogens. This can be caused by complete
isotype- or subclass deficiency due to deletions in the Ig loci of
chromosome 14, but this is rare (3). More often, one or more of the
IgG subclass levels – predominantly IgG2 and/or IgG4 – are below
the normal range in healthy individuals (4),which sometimes leads
to an impaired response to infections with encapsulated bacteria
as will be discussed below. All in all, the acquired variability within
the Ig locus seems to have selected for beneficial changes during
evolution for optimizing or fine tuning the antibody-mediated
immune response.
IgG ANTIBODY RESPONSES
The route by which an antigen enters our body and its chem-
ical composition steers the (secondary) immune reaction into
preferential patterns of class switching. Besides direct B-cell trig-
gering by the antigen itself, a number of secondary signals will
influence differentiation of the B-cell, including recognition by
pattern-recognition receptors like Toll-like receptors and cytokines
produced by other lymphocytes and antigen-presenting cells (5,
6). For example, protein antigens usually trigger B-cells receiv-
ing T-cell help through MHC-class II expressed by the B-cell.
For those antigens, class switching tends to be IgG1 or IgG3,
but can also be IgG4 or IgE. On the other hand, in the absence
of T-cell help, polysaccharide antigens may induce class switch-
ing to IgG2 in particular. B-cells undergoing class switching in
a primary or secondary immune reaction can also go through
subsequent class switching (7), but those events are limited by
the availability of remaining heavy chain genes, not excised from
the genome in previous class-switching events. The relatively
terminal position of the Cγ4 cassette may be one of the rea-
sons why IgG4 responses tend to occur after repeated antigen
exposure (8).
IgG1
Antibody responses to soluble protein antigens and membrane
proteins primarily induce IgG1, but are accompanied with lower
levels of the other subclasses, mostly IgG3 IgG4 (9). Because IgG1
is normally the most abundant subclass, a lack of IgG1 seen in a
variety of primary and secondary antibody deficiencies, can result
in decreased total IgG levels (hypogammaglobulinemia). IgG1
deficiencies, sometimes in combination with other IgG subclass
deficiencies, are associated with recurrent infections (10).
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Table 1 | Properties of human IgG subclasses.
IgG1 IgG2 IgG3 IgG4
General
Molecular mass (kD) 146 146 170 146
Amino acids in hinge region 15 12 62a 12
Inter-heavy chain disulfide bonds 2 4b 11a 2
Mean adult serum level (g/l) 6.98 3.8 0.51 0.56
Relative abundance (%) 60 32 4 4
Half-life (days) 21 21 7/∼21a 21
Placental transfer ++++ ++ ++/++++a +++
Antibody response to:
Proteins ++ +/− ++ ++e
Polysaccharides + +++ +/− +/−
Allergens + (−) (−) ++
Complement activation
C1q binding ++ + +++ −
Fc receptors
FcγRI +++c 65d − − ++++ 61 ++ 34
FcγRIIaH131 +++ 5.2 ++ 0.45 ++++ 0.89 ++ 0.17
FcγRIIaR131 +++ 3.5 + 0.10 ++++ 0.91 ++ 0.21
FcγRIIb/c + 0.12 − 0.02 ++ 0.17 + 0.20
FcγRIIIaF158 ++ 1.2 − 0.03 ++++ 7.7 − 0.20
FcγRIIIaV158 +++ 2.0 + 0.07 ++++ 9.8 ++ 0.25
FcγRIIIb +++ 0.2 − − ++++ 1.1 − −
FcRn (at pH < 6.5) +++ +++ ++/+++a +++
aDepends on allotype.
bFor A/A isomer.
cMultivalent binding to transfected cells. Adapted from Bruhns et al. (2).
dAssociation constant (×106 M−1) for monovalent binding (2).
eAfter repeated encounters with protein antigens, often allergens.
IgG2
Immunoglobulin G-antibody responses to bacterial capsular poly-
saccharide antigens can be almost completely restricted to IgG2 (9,
11–13), and IgG2 deficiency may result in the virtual absence of
IgG anti-carbohydrate antibodies (14), although these responses
can also be compensated for by enhanced levels of other IgG sub-
classes, in particularly by elevated IgG1 and IgG3 levels (15). An
increased susceptibility to certain bacterial infections is associated
with IgG2 deficiency, suggesting a role of IgG2 in the defense to
these pathogens (16). Low concentrations of IgG2 often occur in
association with a deficiency in IgG4 and/or IgA1 and IgA2 (17).
An extensive analysis of anti-carbohydrate reactivities in intra-
venous immunoglobulin revealed that although IgG2 indeed rep-
resents the bulk of the reactivity to many glycans, this is not always
the case (18). IgG1 antibodies have also been reported to prevail
against Haemophilus influenzae b polysaccharide during natural
infections (9). In normal immune responses in healthy individu-
als, IgG1 and IgG3 responses can also be observed, and certainly
against protein-conjugated glycans, which happens in the reaction
to second-generation pneumococcal vaccines (19).
IgG3
IgG3 antibodies are particularly effective in the induction of
effector functions. Being a potent pro-inflammatory antibody, its
shorter half-life may function to limit the potential of excessive
inflammatory responses. However, the finding that some indi-
viduals bearing the G3m allotypic “s” or “15” marker [i.e., G3m
(s)/G3m (15) and G3m (st)/G3m (15, 16) allotypes] also have
IgG3 with prolonged half-life may challenge that assumption
(20). Curiously, IgG3 levels in these individuals do not seem to
be increased, which may be explained by γ3-promotor polymor-
phisms known to affect the frequency of class switching to IgG3
in G3m (g) allotypes, explaining the low concentration in most
G3m (g) homozygous individuals (21, 22). Viral infections in gen-
eral lead to IgG antibodies of the IgG1 and IgG3 subclasses, with
IgG3 antibodies appearing first in the course of the infection (9).
IgG3-dominated responses appear to be rare. A curious example
is the so-called anti-hinge antibodies (23), which bind to the hinge
region of Fab2 fragments but not intact IgG antibodies. Also, anti-
bodies to P and Pk blood group antigens are largely restricted to
IgG3 (24). Responses against other red cell antigens (e.g., RhD)
and platelets (e.g., human platelet antigen 1a), as seen in trans-
fusion and in pregnancies, are often dominated by IgG1, IgG3, or
both (25–27). Decreased IgG3 levels are frequently associated with
other IgG subclass deficiencies (28).
IgG4
Allergens are often good inducers of IgG1 and IgG4, in addition
to IgE. IgG4 antibodies are often formed following repeated or
long-term exposure to antigen in a non-infectious setting and may
Frontiers in Immunology | Immunotherapies and Vaccines October 2014 | Volume 5 | Article 520 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vidarsson et al. Variability, biology, and function of human IgG
become the dominant subclass. Examples are long-term bee keep-
ers and allergic individuals that underwent immune therapy (8,
29–31). In immunotherapy, relief of symptoms appears to corre-
late with IgG4 induction. Switching to IgG4 may be modulated by
IL10, linking this subclass downregulation of immune responses or
tolerance induction (8, 32). IgG4 may also represent the dominant
antibody subclass in immune responses to therapeutic proteins,
such as factor VIII and IX (33–35) and at least some recombi-
nant antibodies such as adalimumab (36). Furthermore, helminth
or filarial parasite infections may result in the formation of IgG4
antibodies (37, 38), and high IgG4 titers can be associated with an
asymptomatic infection (39).
Isolated IgG4 deficiencies are rare; it is uncertain what the
possible consequences are. On the other hand, a group of dis-
orders, nowadays referred to as IgG4-related diseases (IgG4RD),
are characterized by elevated serum IgG4 concentration and tissue
infiltration by IgG4-positive plasma cells and may affect a number
of organs (40, 41). The spectrum of IgG4RD is wide and includes
patients with autoimmune pancreatitis (AIP), Mikulicz’s disease,
hypophysitis, Riedel thyroiditis, interstitial pneumonitis, intersti-
tial nephritis, prostatitis, lymphadenopathy, retroperitoneal fibro-
sis, inflammatory aortic aneurysm, and inflammatory pseudo-
tumor (42). In AIP patients, elevated serum IgG4 (>1.4 g/L) is
observed in 70–80% of the cases, as well as in 10% of pancreatic
cancer patients. However, as 5% of the normal population also
has elevated IgG4 levels, this makes it only suitable for diagnosis
in combination with other features of AIP.
STRUCTURE
Similar to the other isotypes, the IgG immunoglobulin molecule
consists of four polypeptide chains, composed of two identical
50 kDa γ heavy (H) chains and two identical 25 kDa κ or λ light
(L) chains, linked together by inter-chain disulfide bonds. Each
heavy chain consists of an N-terminal variable domain (VH) and
three constant domains (CH1, CH2, CH3), with an additional
“hinge region” between CH1 and CH2 (Figure 1A). Similarly, the
light chains consist of an N-terminal variable domain (VL) and
a constant domain (CL). The light chain associates with the VH
and CH1 domains to form a Fab arm (“Fab”= fragment anti-
gen binding), and functionally, the V regions interact to form
the in antigen-binding region – acquired through differential
assembly of Variable, Diversity (VH only), and Joining gene seg-
ments and inclusion of somatic mutations (43–45), although
their relative contribution to antigen binding varies greatly. Two
heavy chain–light chain heterodimers (HL) combine into a sin-
gle antibody molecule (H2L2) via disulfide bonds in the hinge
region and non-covalent interactions between the CH3 domains
(Figure 2A). The part of the antibody formed by the lower
hinge region and the CH2/CH3 domains is called “Fc” (“fragment
crystalline”).
FIGURE 1 | (A) Crystal structure of an human IgG1 molecule (1HZH)
viewed from two different angles, demonstrating the flexibility of the
two Fab fragments with respect to each other and the Fc tail. The binding
location for FcγR, binding IgG asymmetrically in a 1:1 configuration
(46–49), is indicated by the blue circle (lower hinge, upper CH2) on the
left, and the location of the binding motifs for FcRn, TRIM21, and the
potential site for binding of DC-SIGN on the right (intersection of CH2
and CH3). FcRn, and the potential binding site of DC-SIGN bind IgG in a
2:1 configuration (50–52), respectively, while a dimer of TRIM21 binds
IgG in a 1:1 configuration (53). The N-linked glycan at position 297
attached to each of the heavy chains is shown on the right. (B)The
N-linked glycan found at position 297 can be found as a core structure,
common to all IgG found in human beings and rodents (core structure
indicated with a red dashed line), but can be found with either an
addition of fucose, bisecting N -acetylglucosamine (GlcNAc), one or two
galactose, and one or two sialic acid residues.
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FIGURE 2 |The schematic layout of the IgG subclasses and isomers
thereof. (A)The IgG subclasses, indicating how the different heavy and light
chains are linked, the length of the hinge, and the number of disulfide bridges
connecting the two heavy chains. For orientation, and comparison with
Figure 1, the location of the hinge, CH2, and CH3 domains are shown. The
classical A/A isoform of IgG2 with four different disulfide bridges between the
two heavy chains is depicted here, but in (B) the B/B form, with only two
disulfide bridges and alternative linkages of the light chain to the heavy chain
form is shown, together with the intermediate A/B form. (C) Isomers of IgG4
resulting in half-molecule exchange. On the far left and far right, two
classically depicted IgG4 clones in slightly different colors are shown just after
secretion from B-cells. These are connected with two inter-chain disulfide
bridges. However, these are in fact in equilibrium where these are reduced
creating forms without covalent linkages between the symmetric molecules.
This form can either revert back to covalently linked form or swap heavy
chains in a stochastic process with that of neighboring IgG4 molecule creating
a asymmetric bispecific IgG4 (bottom middle) that is also in flux, reverting into
covalently linked IgG4 (top, middle). By this process, most IgG4 found in
human beings (expressing the IgG4-R409 allotype, see text for more details
and Figure 3) are monovalent-bispecific molecules.
The global structures of the four human IgG subclasses are
very similar (Figures 1 and 2A), but with important differences
between each subclass that affect their binding to accessary mol-
ecules and receptors, affecting their functionality (Table 1). The
four subclasses show over 90% homology in amino acid sequence,
with differences that are not randomly distributed. Much variation
is found in the hinge region and N-terminal CH2 domain, whereas
fewer amino acid differences are found in the other domains.
Of these, least is known about the functional consequences – if
any – of structural variations found within the CH1 domain. On
the other hand, structural differences in the CH2/CH3 domains,
forming the Fc tail, are relatively well studied.
The residues most proximal to the hinge region in the CH2
domain of the Fc part are responsible for effector functions of
antibodies as it contains a largely overlapping binding site for C1q
(complement) and IgG-Fc receptors (FcγR) on effector cells of the
innate immune system.
A highly conserved N-linked glycosylation site at position 297
is located at the interface between the two CH2/CH3 forming
the Fc of an IgG molecule (Figure 1A) that is both responsi-
ble for subtle but important changes of quaternary structure of
the Fc – allowing for a more exposed docking-site for FcγR. As
discussed further below, these glycans also directly participate
in the FcγR binding, but can also modulate these interactions
through highly specific modifications of the N297 glycan – changes
that seem to be regulated during specific immune responses in
human beings (54, 55). Although this glycosylation site is often
regarded as the only glycosylation site in IgG, the V region of
approximately 10–15% of all antibodies is also glycosylated. These
sites most often arise through VDJ-recombination or somatic
hypermutation (43), and this glycosylation has been reported to
affect antigen-binding characteristics (56–59) and allowing bind-
ing to regulatory lectins. This, in turn, can also modulate the
activation-threshold required for B-cell stimulation, and has been
described as a positive selection signal in certain types of follicular
lymphomas (60).
The interface between the CH2–CH3 domains also contains
the binding site for the neonatal Fc receptor (FcRn), responsible
for the prolonged half-life of IgG, placental passage, and transport
of IgG to and from mucosal surfaces. Little variation exists in this
region, with FcRn binding only minimally affected, except perhaps
for IgG3 as discussed further below.
However, the binding profiles of FcγR and C1q to the different
IgG subclasses go hand in hand (Table 1); each IgG subclass having
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its distinctive pattern that has been investigated in detail. How the
differences in the primary sequences of the IgG subclasses (Fc and
hinge) lead to variations in tertiary structural elements, thereby
critically influence the properties of each subclass, is the subject of
the following sections.
STRUCTURAL VARIATION IN THE HINGE REGION
The hinge region forms a flexible linker between the Fab arms and
the Fc part. Length and flexibility of the hinge region varies exten-
sively among the IgG subclasses (Figure 2) (61). This affects the
possible conformations of the Fab arms relative to the Fc domain
as well as to each other. The hinge exon of IgG1 encompasses
15 amino acids and is very flexible. IgG2 has a shorter hinge than
IgG1, with 12 amino acid residues. The lower hinge region of IgG2
(actually encoded by the CH2 region) also has a one amino acid
deletion (lacking one of the double Glycines found at position
235-6), resulting in IgG2 having the shortest hinge of all the IgG
subclasses. In addition, the hinges of IgG2 are even more rigid due
to a poly-proline helix, stabilized by up to four (with some excep-
tions discussed below) extra inter-heavy chain disulfide bridges
(Figure 2). These properties restrict the flexibility of the IgG2 mol-
ecule. Similarly, the hinge region of IgG4 also contains 12 amino
acids and is thus shorter than that of IgG1. Its flexibility is inter-
mediate between that of IgG1 and IgG2 (62). Unlike IgG2, it does
encode for the CH2-encodied glycines 235-6 in the lower hinge
(Figure 3A).
FIGURE 3 | IgG subclasses and IgG allotypes. (A) All differences
between the IgG isotypes depicted schematically according to their
localization (numbered below a graphical representation of the gene) in the
different domains and exons depicted above the sequence. Bold
underlined numbers (EU numbering) contain isoallotypic variant at that
position. Amino acids depicted in bold varies from the other subclasses,
but amino acids depicted in italics are present in two subclasses. The
green boxed amino acids numbers are residues involved in binding to C1q,
in red amino acids involved in FcγR binding, and in blue residues involved
in binding to FcRn. “-“ instead of a letter for amino acid stands for the
missing G236 residue in IgG2. (B)The amino acid variation found within
IgG1, IgG2, and IgG4 allotypes, and (C) among the IgG3 allotypes. The
presence or absence of the two kinds of IgG3-hinge exons (a, and b) are
indicated by “+” or “–” in (C). For (B,C), amino acids in bold are those
unique for subclass or allotype, and those underlined isoallotypes, as this
amino acid is also found in other subclasses at this position. The unique
IMGT numberings and a representative sequence accession number are
indicated on the right. For some of the allotypes, the IMGT numberings
are represented by several different genes, but encoding for identical
hypothetical proteins.
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IgG3 has a much longer hinge region than any other IgG sub-
classes or Ig human isotype, i.e., about four times as long as the
IgG1 hinge, containing up to 62 amino acids (including 21 pro-
lines and 11 cysteines), forming a poly-proline helix with limited
flexibility (63, 64). The exact length of the hinge varies between
allotypes of IgG3, which apparently has undergone much more
evolutionary radiation than the other subclasses (Figures 3B,C)
as discussed below. In IgG3, the Fab fragments are relatively far
away from the Fc fragment, giving the molecule a greater flexibil-
ity. This long hinge of IgG3 is a result of duplications of a hinge
exon, encoded by one exon in IgG1, IgG2, and IgG4, but up to
four exons in IgG3. One of those exons is common to all IgG3
allotypes, but it also has 1–3 copies of a homologous second type
of IgG3-hinge exon (Figure 3C). The elongated hinge in IgG3 is
also responsible for its higher molecular weight compared to the
other subclasses. The difference in hinge flexibility influences the
relative orientation and movement of the Fab arms and Fc tail of
the IgG antibody.
Binding sites for C1q and/or FcγR may be partially or com-
pletely shielded by Fab arms, affecting binding of the IgG
to these molecules. The relative flexibility of the Fab arms
with respect to the Fc differs between subclasses as follows:
lgG3> lgG1> lgG4> lgG2 (62, 65), which also reflects the rel-
ative binding of these subclasses to FcγR and C1q, although this
only partially explains the respective activities of the IgG subclass,
as discussed elsewhere in this review. This flexibility also affects
antigen-binding capacity and immune complex formation.
INTER-CHAIN DISULFIDE BONDS
The four IgG subclasses also differ with respect to the number of
inter-heavy chain disulfide bonds in the hinge region (Table 1;
Figure 2A). In addition, both IgG2 and IgG4 are found as several
isomers, in which the hinge disulfide bonds are differentially inter-
connected (see below). Another structural difference between the
human IgG subclasses is the linkage of the heavy and light chain
by a disulfide bond. This bond links the carboxy-terminal cys-
teine of the light chain to the cysteine at position 220 (in IgG1)
or at position 131 (in IgG2, IgG3, and IgG4) in the CH1 domain
(Figure 2A). These two positions are spatially juxtaposed and the
essential structure and function of the molecule appears to be con-
served between the two types of linkage between heavy and light
chain.
HINGE ISOMERS IN IgG2 AND IgG4
In IgG2, structural hinge isomers have been observed as a result
of alternative formation of disulfide bonds between the cysteines
in the hinge region of the heavy chains and those involved in the
formation of disulfide bonds between the light and heavy chain
(Figure 2B) (66, 67). These isomers were found particularly in
IgG2 antibodies with kappa-light chains, but much less for lambda
light chains. The major forms are the classical A form, with four
disulfide bridges between the two IgG2 heavy chains, and the B
form in which one hinge cysteine forms a disulfide bond with the
light chain. However, other configurations exist (67, 68), as these
isoforms apparently form independent of each other, giving rise
to A/A, B/B, but also A/B isoforms (Figures 2A,B). FcRn binding
does not seem to be different for the different isomers (69). IgG2
has also been reported to form covalent dimers (70), which might
be regarded as an additional isomer.
Two isomers of IgG4 differing in the disulfide bonding of hinge
cysteines coexist. The core hinge of IgG is formed by a CXXC
motif, also found in redox-reactive proteins such as thioredoxins
(71). Compared to IgG1, with a relatively rigid CPPC motif (72),
intra-chain disulfide bonds are more easily formed between these
cysteines found at positions 226 and 229 in IgG4, which possesses a
CPSC core hinge (Figure 2C). The result is an observable amount
of non-covalently linked half-molecules (consisting of one heavy
and one light chain, HL, as opposed to the classical configura-
tion of H2L2) in addition to covalently linked inter-chain isomers
(Figure 2C) (73, 74). An S228P mutant of IgG4, thus with an
IgG1-core hinge, does not form half-molecules, which is in agree-
ment with the finding that this species does not occur in IgG1. The
process is reversible but depends on redox conditions. Formation
of the intra-chain isomer (half-molecules) is an important step in
the “Fab arm exchange.”
IgG4 Fab ARM EXCHANGE
In vivo, half-molecules of IgG4 recombine randomly with other
half-molecules of IgG4, combining specificities of two IgG4 mol-
ecules, effectively resulting in monovalent-bispecific antibodies
(Figure 2C) (75,76),and is controlled by redox conditions (74,77).
The unique S228 in the core hinge of IgG4 allows formation of the
intra-chain isomer, and R409 (rather than the equivalent lysine
in IgG1) results in weaker CH3–CH3 interactions (Figure 3A)
(77, 78). Both determinants appear to be required to observe
Fab arm exchange in vivo (74) and have been observed for the
therapeutic IgG4 antibody natalizumab (79). The functional con-
sequence of this are at least twofold. The resulting IgG4 antibody
cannot effectively crosslink the target antigen. Furthermore, mul-
tivalent target binding is not possible for bispecific antibodies,
resulting in a lower avidity, although the affinities of IgG4 antibod-
ies are generally high. In combination with the observations that
IgG4 responses seem to dominate after repeated antigen exposure
(e.g., bee venom), and because IgG4 has low affinity to activat-
ing FcγR while retaining relatively high affinity to the inhibiting
FcγRIIb (Table 1), this may serve as an evolutionary way to pre-
vent excessive immune responses against these sterile antigens not
posing infectious threats. IgG4 has, therefore, been characterized
as “blocking antibody,” especially in the context of allergy, where
it may compete with IgE for allergen binding (8).
ALLOTYPES
In addition to isotypic variation, allelic variation is found among
the IgG subclasses (Figure 3) (80). These polymorphic epitopes of
immunoglobulins that can differ between individuals and ethnic
groups (81) were originally discovered on the basis of serologi-
cal findings (82), as immunogenic determinants were found on
IgG from some individuals but not others. Subsequently, allotypic
variations were genetically analyzed, and a number of structural
determinants identified (83–86). A large number of polymor-
phisms were found in IgG, a finding made useful for example
in paternity testing and forensic medicine before HLA typing
became available (82). Exposure of an individual to a non-self
allotype can induce an anti-allotype response, and may occur
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in transfused individuals (82) and has even been described in a
pregnant woman (87). However, not all variations in IgG amino
acid sequence lead to determinants that are immunogenic because
some determinants are found in other isotypes, and are there-
fore called isoallotypic variants (Figure 3). Other variations in
amino acid sequence can be present at sites that are minimally
exposed and, therefore, may not result in determinants that can
be serologically discriminated. Therefore, the original alphabeti-
cal and numerical designation systems (Gm or Genetic marker,
including a subclass designation, e.g., G1m for IgG1 (81), based
on serology, do not fully cover the structural variation among
different allelic forms of IgG subclasses. This is particularly true
for IgG3, which shows extensive polymorphisms – often of isoal-
lotypic origin (Figure 3C) (83). An example is the non-a or
nG1m (a) determinant (E and M at positions 356 and 358,
respectively) that can also be found on IgG2, 3, and 4 (81).
Therefore, in order to refer uniquely to a particular polymor-
phic variant, it is advisable to use the IMGT allele names rather
than either the alphabetical or numerical allotype nomenclature
(Figure 3).
The main allelic forms for IgG1 (Figure 3B) are G1m (z,a), G1m
(f), and G1m (f,a) (81, 88). The G1m (f) allele is only found in
Caucasians, whereas the G1m (f,a) allele is common in Orientals,
but other variants, G1m (z,a,x) and G1m (z,a,v), have also been
described (89, 90). Several allelic forms of IgG2 are known, includ-
ing G2m (..) variants, which, together with IgG4, serve as examples
of IgG variants without actual allotypic determinants, as here the
amino acids present at position 189 and 282 are isoallotypic and
also found in the other subclasses (Figures 3A,B) (91, 92). For
IgG3, many allelic forms are known, with the most important
ones encoding for amino acid changes shown in Figure 3C.
Since some allotypes have proven to be immunogenic, they
may be relevant to consider when developing therapeutic anti-
bodies. Treatment using therapeutic monoclonal antibodies can
in principle also lead to an anti-allotype response. However, to
date, little evidence has been found for significant anti-allotype
responses, e.g., adalimumab (93) or infliximab (94). There are no
known allotypic variations that result in a functionally different
antibody, except for IgG3, where a few isoallotypic variants result
in extended half-life (discussed in Section “FcRn”). Furthermore,
several polymorphisms in the CH3 domain affect the CH3–CH3
interdomain interactions, which for different IgG3 isoallotypic
variants result in these interactions to vary multiple orders of mag-
nitude, which potentially has consequences for e.g., C1q binding
(77). Interestingly, plasma IgG concentrations of an individual
appear to correlate with Gm allotype (21, 28, 95), which may be
related to the actual single-nucleotide polymorphisms (SNP) caus-
ing the allotypes themselves, or silent SNP, that in turn may affect
unfavorable codon-usage or alter secondary mRNA structures
affecting transcription (96–98). In addition, the allotype may also
affect class-switching efficiency and thereby serum concentrations,
through variations within the non-coding switch regions inherited
haplotype. This is because these sterile promoters undergo tran-
scription preceding actual class switching (21, 22, 98), and allotype
differences found within these region affect class-switching effi-
ciency directly, explaining the lower levels found of IgG3 in g3m
(g) individuals compared to G3m (b).
For IgG4 no serologically important allotypes are known to
exist, but isoallotypes have been described (81). Furthermore, a
polymorphic variant exists (K409 instead of R409) that is unable
to participate in Fab arm exchange (84). It is unknown if carry-
ing this variant has any biological consequences (e.g., because this
kind of IgG4 can potentially crosslink antigens as opposed to the
classical monovalent IgG4 type), as the apparent low allelic fre-
quency makes homozygotes rare, at least in the western-European
population.
In conclusion, most of the genetic variation in IgG have poten-
tial implications far beyond the original serological findings, as
non-serologically important variations exceed those by far. As
of yet, we still do not fully know the extent of these variabil-
ity as this has not yet been revisited by modern techniques.
This includes on the number of unknown variants, the fre-
quency by which they appear within and between populations.
This can have functional consequences, on expression levels (21),
half-life, FcγR binding [antibody-dependent cell-mediated cyto-
toxicity (ADCC), ADCP], tendency to form oligomers (99) and
activate complement, and influence on immunogenicity – again
within and between populations – and, therefore, have important
consequences for antibody-mediated immunotherapies.
GLYCOSYLATION
Immunoglobulin G contains a conserved glycan at position N297
of the heavy chains. In addition, roughly 10–20% of the Fab
have N-glycosylation sites in the binding region. The core struc-
ture of the IgG glycans comprises N -acetylglucosamine (GlcNAc)
and mannose residues (Figure 1B). This can be further extended
with galacose, sialic acid, core fucosylation, and bi-sected GlcNAc
(Figure 1B). Several dozen IgG-Fc glycoforms have been found
in healthy human serum, of which only a handful represent the
dominant form (fucosylated species in one of the following con-
figuration: without galactose, with one- or two galactose residues,
or with two galactose and a single sialic acid residue, Figure 1B)
(54, 100, 101). Between Fab and Fc glycans, there are several dif-
ferences in glycosylation, those most pronounced being markedly
increased levels of bisection, galactosylation, and sialylation in the
Fab glycans (including di-sialylation hardly seen in the Fc), but
reduced fucosylation (~94% for Fc, vs ~70% for Fab) (100, 102).
This is partially due to accessibility for glycosyltransferases and
glycosidases, Fab sites are generally more accessible compared to
the conserved site in the Fc, which lies more buried between the
two heavy chains (Figure 1A). In addition, glycosylation levels are
also controlled by availability of glycosyltransferases in the B-cells.
In several health and disease settings, a shift toward certain Fab-
and Fc-glycoforms of antibodies has been reported (54, 55, 103).
This shift may occur through epigenetic influence on expression
of glycosyltransferases (104), which is clearly affected by various
factors including, age, pregnancy, hormones, cytokines, bacter-
ial DNA, and food metabolites (105–107), although the complete
working mechanism of regulation of expression in B-cells has to
be determined.
As mentioned above, the composition of the N297 glycan influ-
ences the quaternary structure of the Fc. Interactions of the glycan
with the protein backbone stabilize the Fc (108). Addition of the
Fc-glycan gives the IgG-Fc a more open conformation, allowing
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binding to FcγR (109, 110). In addition, the glycan is in close prox-
imity to the FcγR itself, contribution to the binding through glycan
protein binding (110). However, perhaps even more important
is the fact that human FcγRIIIa and FcγRIIIb express a con-
served glycan at position 162, entering the Fc-space confining the
Fc-glycan, enabling a direct glycan–glycan interaction (46, 111).
Our knowledge on how the different glycoforms affect the effec-
tor function of IgG is still in its infancy, but some aspect have been
becoming increasingly clear as summarized below.
FUCOSYLATION
It has been known for quite some time that core fucosylation of
the IgG-Fc affects binding to FcγRIIIa (112), with non-fucosylated
antibodies binding FcγRIIIa much stronger. This higher affin-
ity translates into higher ADCC and phagocytosis of targets by
these antibodies (54, 112), and has been put to use in therapeu-
tic antibodies, like rituximab, to increase the efficacy of treatment
[reviewed by Ref. (113, 114)]. More recently, it has become clear
that this also applies to FcγRIIIb expressed on granulocytes (54,
115, 116). The molecular nature of this increased affinity is dis-
cussed below (see FcγRIIIa). After vaccination, or apparently after
normal immune responses, the IgG responses in human beings are
restricted to IgG with core fucose attached, as seen against soluble
proteins during influenza or tetanus toxoid vaccination (117). This
also reflected by the fact that ~94% of IgG-Fc glycopeptides are
fucosylated in total serum. Even more strikingly is the fact that IgG
fucosylation is prevented in some immune responses against par-
ticulate antigens, e.g., red blood cells and platelets (54, 55, 103), but
also witnessed in some elite controllers of HIV (57). Thus appar-
ently, FcγRIII-mediated IgG responses can be fine-tuned through
IgG fucosylation toward more pro- or anti-inflammatory effects.
BISECTION
Slight changes in bisection have been detected for some antigen-
specific IgG responses (54, 102, 103, 118). Little is known about
the importance of the biological implication of these changes. It
has been described that fucosylation and bisection occurs in a rec-
iprocal manner, with proximal bisection blocking fucosylation of
IgG, making it difficult to discriminate the effect of bisection from
core fucosylation (119–121).
GALACTOSYLATION
To our knowledge, no data have been published to date on the
influence of galactosylation on the level of antigen-specific IgG.
Immunization seems to result in a transient increase in galactosy-
lation of antigen-specific IgG in human beings, while having no
effect on total IgG galactosylation (117). However, general decrease
in galactosylation has been found in several autoimmune diseases
[reviewed in Ref. (122)], suggesting degalactosylated IgG to be
more pathogenic, or galactosylated IgG to have anti-inflammatory
activity. This includes rheumatoid arthritis, a disease that often
goes into remission during pregnancy – correlating with the
general increase in galactosylation in pregnancy (123).
SIALYLATION
As the terminal – and the only charged – sugar moiety, sialylation
has been proposed to have the most effect on the structure of the
Fc domain of the antibody, by closing the binding site for activat-
ing FcγRs, but opening up a cryptic binding site for DC-SIGN in
the CH2-CH3 interface (50). In proof of this, actual comparisons
of IgG with or without Fc-sialylation have confirmed this (124),
and mouse IgG decreased affinity to mouse FcγR in general (125),
although systematic analyzes of the importance of this for human
IgG-FcγR binding is lacking. Increased sialylation of IgG generally
follows increased galactosylation as galactosylated IgG is the sub-
strate for sialyltransferases (Figure 1B) (54, 103, 126). Binding to
DC-SIGN sialylated antibodies has been suggested to have strong
immunomodulatory function as described below (see DC-SIGN).
EFFECTOR MECHANISMS
BINDING TO EFFECTOR MOLECULES
Antibodies link the adaptive immune system with the effector
mechanisms of the innate immune system. They form a bridge
by combining antigen-binding sites with binding sites for many
innate receptors and adaptor molecules. The effector mechanisms
that will be triggered vary between the different immunoglobulin
subclasses. Typically, IgG1 and IgG3 are potent triggers of effec-
tor mechanisms, whereas IgG2 and IgG4 will induce more subtle
responses, and only in certain cases. However, these antibodies
remain capable of neutralizing virus particles and toxins. Below,
binding to C1q and FcRns is discussed, emphasizing the structural
aspects that differ between the subclasses (Table 1).
C1q
Upon binding to target surfaces, IgG, as well as IgM, can activate
complement. Complement activation is initiated through binding
and subsequent activation of C1q, leading to deposition of C3b to
further opsonize the target, but also to the formation of the mem-
brane attack complex, C5–C9, causing disruption of the targeted
bilipid membrane (127). IgG1 and IgG3 can efficiently trigger this
classical route of complement (128), but IgG2 and IgG4 does so
much less efficiently or only under certain conditions for IgG2.
This is due in large part to the reduced binding of C1q to the latter
subclasses (128–130), although it has also been described that in
addition to C1q binding, downstream events of the complement
cascade (C4b deposition) are differentially affected by the differ-
ent IgG subclasses (128). Residues in the CH2 region important
for C1q binding include L235, D270, K322, P329, and P331 (130–
133). In IgG2, reduced C1q binding appears to be largely caused
by residue A235 (which is Leu in other subclasses) (132), whereas
in IgG4, P331 is – at least in part – responsible for the reduced or
absent binding of C1q (130, 133). Structural determinants in the
middle or “core” hinge region (residues 226–230) can influence
the binding of C1q (134). On the one hand, rigidity in this region
contributes favorably to C1q binding, whereas removal of cysteine
bonds negatively affects binding. It has also been suggested that
the relatively long hinge of IgG3 makes the C1q binding site more
accessible resulting in more efficient complement activation (135,
136). However, IgG3 engineered with a short IgG4 hinge binds
C1q efficiently, although complement activation was somewhat
reduced (137).
Interestingly, IgG has recently been suggested to form hexamers
by interactions through the CH2–CH3 interface when opsonized
on target surfaces, forming an optimal platform for the hexameric
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configuration of C1q (99). These data are supported by mutation
in this interface, e.g., I235 in the CH2 and H433 in the CH3 that
individually affect complement activation through C1q (99).
Curiously, engineered IgG1/3 hybrids with an IgG1-CH1, and
hinge regions were found more potent in complement activation
compared to wild-type IgG3, with the largest contribution arising
from the CH1 domain swap (138). Conversely, the binding of C1q
to IgG4 can be influenced by shielding of the potential binding
site by Fab arms (74, 136, 139, 140). The orientation of the Fabs
have been modeled to be perpendicular to that of the hexameric
platform of IgG on solid surfaces and in solution (99) and may
thereby affect C1q biding, although this needs to be confirmed.
IgG4 also results in less complement activation by forming small
immune complexes, probably because of their monovalency, and
in this way can even reduce complement activation by IgG1 anti-
bodies (141). Although the short hinge of IgG2 may lead to similar
shielding of the potential C1q binding site, a notion that fits with
its general poor activation of the classical complement cascade,
IgG2 can activate this cascade at high densities of surface antigens,
as is the case for polysaccharides – to which IgG2 antibodies tend
to form (19, 142, 143). At these high epitope densities, IgG2 may
be more likely to efficiently form hexamers, increasing the avidity
of this subclass for C1q substantially (99).
Fcγ-RECEPTORS
FcγR bind to a region partially overlapping the C1q binding site.
The binding of IgG to these receptors has been studied in detail.
For all FcγR interactions, the stretch of amino acids comprising the
N-terminus of the CH2 domains and strands adjacent in the three
dimensional immunoglobulin fold are important for binding. In
general, this encompasses amino acids 234–239, 265–269, 297–
299, and 327–330 (110, 144). However, each of the IgG subclasses
has a unique binding profile to each FcγR (Table 1) (2), and their
expression profiles are highly variable between different immune
cells of myeloid and NK cell origin (145). A major distinction can
be made between IgG1/IgG3 that interact efficiently with most
FcγR, and IgG2/IgG4, which show reduced affinity to a number
of FcγR. Furthermore, monomeric IgG3 binds more efficient than
monomeric IgG1 to FcγRIIa, FcγRIIIa, and FcγRIIIb, and binding
efficiency of complexed IgG3 to all FcRns exceeds that of IgG1 (2).
Structural determinants responsible for the differences between
IgG1 and IgG3 are still unknown. Below, we discuss structural dif-
ferences that are known to be responsible for the subclass-specific
variations.
FcγRI
Although FcγRI is often referred to as a single entity, FcγRI consists
of three homologous genes on the short arm of chromosome one
(146), and several alternative splice variants have been described
(147). However, only the existence of the full-length form, FcγRIa,
consisting of three extracellular domains has been studied in detail.
The gene encoding for the potential FcγRIb variant, potentially
consists of a nearly identical receptor with only the two N-terminal
extracellular Ig-domains, but retaining the intracellular cytoplas-
mic tail, while FcγRIc would also lack the cytoplasmic tail and
transmembrane region, and would, therefore, be predicted to rep-
resent a secreted form (Figure 3). FcγRIa receptor binds all human
IgG subclasses except IgG2, and unlike the other FcγR, contains its
unique third membrane-proximal immunoglobulin domain that
is also responsible for its higher affinity to IgG (148). Mutations
of IgG1 in the lower hinge to the IgG2 equivalents, in particular
E233P, L235A, and G236Delta, abrogate binding (149–153). Bind-
ing to FcγRI is reduced for IgG4 (2), and both P331S and L234F
are implicated to account for the reduced binding in comparison
to IgG3 (152), but P331 may not be important for binding of IgG1
(151, 153). An IgG3 with a partially deleted hinge was found to
have reduced binding to FcγRI and FcγRIIa (154).
FcγRIIa
FcγRIIa is the most widely expressed FcγR on myeloid cells and
has been described as the only FcγR with significant binding to
IgG2 (2, 155–157). Binding is more efficient for the 131H (“low-
responder,” LR) variant than the 131R (“high-responder,” HR)
variant (nomenclature based on differential binding to mouse
IgG1, which binds the HR much better) (155). Binding affinity
varies among subclasses as follows: IgG3> IgG1> IgG4= IgG2.
Recently, a crystal structure of the complex of IgG1 Fc with FcγRIIa
was published (144), and contact residues relating to differences
in subclass binding include L234, L235, G236 in the lower hinge,
and the structurally adjacent A327. Significantly, the 131R-site
in FcγRIIa is also in close proximity to the lower hinge in this
co-crystal structure. Thus, the lowered binding affinity of IgG2
to FcγRIIa, and the differential binding to the HR/LR-form of
FcγRIIa, may also be attributed to differences in the hinge of IgG2.
FcγRIIb/IIc
The extracellular domain of the inhibiting FcγRIIb is iden-
tical to the activating FcγRIIc that is expressed in ~11%
of individuals (158, 159). Binding to the inhibitory receptor
FcγRIIb or IIc is weak for all subclasses, generally preferring
IgG3= IgG1= IgG4> IgG2. Interestingly, dissociation constants
for binding of monomeric IgG1 and IgG3 are similar, but immune
complexes of IgG3 seem to bind more efficiently compared to IgG1
(2). Binding to most activating FcRns is lower for IgG4 compared
to IgG1, but this is not the case for the inhibitory receptor FcγRIIb.
This altered balance between binding to activating receptors in
comparison to inhibitory receptors may be an important feature
of IgG4 that contributes to its low pro-inflammatory capacity.
FcγRIIIa
Two allotypic variants of FcγRIIIa exist: F158 and V158. The V158
variant has greater affinity for all subclasses, and for IgG3, binding
efficiency approaches that of FcγRIa (2), with general affinities
following IgG3> IgG1>> IgG4> IgG2. Besides changing amino
acids 233–236 from IgG1 to the IgG2 equivalents, A327G (Ala
present in IgG1 and IgG3, Gly in IgG2 and IgG4) also results in
decreased binding (151). Binding affinity of FcγRIIIa seems to
be particularly sensitive to core fucosylation of the N-linked gly-
can at N297 of the Fc tail of IgG, as its binding affinity can be
enhanced up to 50× times – with corresponding increase in effec-
tor function – if the Fc tail is not fucosylated (160, 161). Recent
work by Ferrara et al. has pinpointed this interaction to be due
to carbohydrate–carbohydrate interactions between the glycan on
N297 of the heavy chain and glycosylation of FcγRIIIa at position
162 – a position unique to both FcγRIIIa and FcγRIIIb (46).
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FcγRIIIb
There are also functional allotypic variations of the neu-
trophil FcγRIIIb, referred to as human neutrophil antigen 1
(NA1/HNA1a) and (NA2/HNA1b) (162). The FcγRIIIb-NA1
form is capable of better ingestion of IgG1- or IgG3-opsonized
particles than RIIIb-NA2 (163). FcγRIIIb generally binds IgG1 and
IgG3 but not IgG2 and IgG4, with IgG3 binding better than IgG1
(2). A crystal structure of the complex of IgG1 Fc with FcγRIIIb
reveals amino acids 234–238 to be important contact residues,
and the subclass-specific variation in this area again can explain
the lack of binding of IgG2 and IgG4 to this receptor (47, 110).
FcRn
In the 1960s, the existence of a receptor responsible for the unusu-
ally long half-life of IgG (3 weeks, Table 1) and efficient transport
from mother to young was first proposed by Brambell (164, 165).
This was later confirmed by various groups and eventually cloned
and identified as the neonatal FcRn (166–169).
Structurally, FcRn is strikingly similar to MHC-class I mol-
ecules (51, 52). Like MHC-class I and other MCH-class I-like
molecules, FcRn is co-expressed with the non-glycosylated 12 kD
β2-microglobulin, encoded on chromosome 15. The α-chain of
human FcRn, a 45 kD polypeptide chain, is encoded on chromo-
some 19 at a locus harboring various other immune receptors (e.g.,
KIR, LAIR-1, CD89, CEACAM). Unlike FcRn from mice and rat,
the human FcRn has only one potential glycosylation site (N102).
It is located on the opposite face to the IgG-binding site and is
also shared with that of all known FcRn sequences (mouse, rat,
human being, macaque, pig, sheep, bovine, dromedary, and pos-
sum). FcRn does not bind its ligand at physiological pH (7.4).
Only in the acidic environment of endocytic vacuoles (pH≤ 6.5),
where solvent exposed histidine residues in IgG are protonated,
does binding to FcRn take place (169–171). Histidine residues
within the Fc tail of IgG (CH2-CH3 interface) are critical for high
affinity binding to residues within β2M and FcRn α-chain (51,
52, 151). H435 sits at the heart of this interface, and the lowered
affinity of R435-containing allotypes of IgG3 to FcRn explains
their shortened half-life and lowered placental transport (Table 1).
Consequently, IgG3 has a normal half-life of 3 weeks and is trans-
ported efficiently across the placenta in individuals containing
H435-containing IgG3 allotypes (g3m, 15, or 16) (20, 172).
That FcRn protects IgG from degradation has been confirmed
by mouse models: IgG half-life is decreased in FcRn or β2-
microglobulin deficient mice (166–169). Four times as much IgG is
saved by FcRn-mediated recycling than is produced (173). While it
was originally proposed that FcRn expression on endothelial cells
is responsible for IgG recycling (174), later studies have shown that
the strong FcRn expression on myeloid cells contributes equally
to the half-life extension in mice (175). Likewise, overexpres-
sion of FcRn in transgenic animals results in higher IgG serum
levels (176).
However, FcRn starts its function early in life by transport of
IgG – and thereby humoral immunity – across the placenta from
mother to young (168, 177–179) and in rodents also after birth by
transport from mothers milk in the gut of suckling neonates. In
rats, this FcRn expression is downregulated in the small intestines,
which correlates with degradation of IgG in these cells (180).
In adult life, FcRn is expressed on many epithelial cells, and con-
tinues to function in IgG transport across FcRn expression epithe-
lial barriers (181). FcRn is able (in all species) to bi-directionally
transcytose cargo across polarized (both epithelial and endothe-
lial) cells, but the net transport direction depends on the tissue
(182–184). E.g., in syncytiotrophoblasts of the placenta, transport
is directed away from the apical toward basolateral surfaces, while
in the blood–brain barrier, it seems reversed (182–184) (abluminal
to luminal or brain to blood); however, the involvement of FcRn
in this transport is still debated (185).
Immunoglobulin G or IgG-antigen complexes have been
described to be transported across mucosal surfaces, such as the
intestinal cavity or respiratory epithelium, and thereby to func-
tion in immune surveillance (177, 181, 186, 187). With this role
in mucosal immunity, it complements sIgA in immunoregulatory
function as reviewed in Ref. (188).
As IgG can transport fully folded and functional proteins across
epithelial barriers, this offers new possibilities for FcRn as an
endogenous receptor to transport Fc-Fusion proteins or vaccine
antigens across otherwise impermeable epithelial surfaces (181).
On mucosal cells, FcRn has been found to transport IgG and
be involved in antigen sampling (177, 181, 187), and its expres-
sion on phagocytic cells (181, 189) has recently been found to
enhance phagocytosis capacity of IgG-opsonized particles (190,
191). On antigen-presenting cells, this ingestion of IgG-complexes
can lead to enhanced presentation (192–194). Similar to phago-
cytosis responses, the enhanced presentation likely requires the
external sensing and cellular activation through FcγR and pattern-
recognition receptors, handing the IgG-Antigen cargo over to
FcRn at low pH (191, 192, 195). Thus, immunoglobulin activi-
ties including extended half-life, transport to young, and antigen
sampling seems to be orchestrated through a single receptor, the
MHC-class I-like FcRn. In contrast, other effector functions of
IgG, such as phagocytosis and antigen presentation seem to be
mediated by both FcRn and classical FcγRs.
ALTERNATIVE RECEPTORS FOR IgG
FcRL
Fc receptor-like proteins, consisting of six members (FCRL1-6)
were originally identified as homologs of FcγR but were for a long
time regarded as orphan receptors, mostly expressed on B-cells.
Recently, however, FcRL4 and in particular FcRL5 were found to
bind immunoglobulin as well, with the former recognizing IgA,
IgG3, and IgG4, while FcRL5 binds all IgG subclasses similarly well,
but not IgA. Both these receptors are expressed on B-cells, express
an ITIM, and are known to downregulate B-cells after BCR cross
linking through recruitment of SHP-1 (196, 197). Although FcRL5
seems broadly expressed on B-cells populations (198), FcRL4 is
only expressed on subepithelial tissue B-cells (199) reportedly of
mucosal origin, suggesting that perhaps this receptor is involved
in negative feedback inhibition through antigen-specific IgG and
IgA, respectively.
TRIM21
Tripartite motif-containing protein 21 (TRIM21) is a cytosolic
protein expressed in almost all cell types but highly expressed
in immune cells. TRIM21 previously known as an autoantigen
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involved in several autoimmune diseases, e.g., systemic lupus ery-
thematosus (SLE) (200). Later, TRIM21 was found to bind IgG
with nanomolar affinity (53, 201). TRIM21 binds IgG in the Fc
domain at the CH2–CH3 interface similar to FcRn and protein
A/G, it competes for binding to IgG with protein A/G, and binding
is independent of N-glycosylation of the CH2 domain (202). Later,
it was demonstrated that TRIM21 functioned as an immunological
sensor, targeting IgG-opsonized virus and bacteria for antibody-
dependent intracellular neutralization by the ubiquitin-dependant
proteosome (203–206). The detection of antibody opsonized virus
by this receptor activates, requires proteasome and the ATPase
and unfoldase VCP (206, 207). It also activates further signaling,
and innate immunity responses are activated, characterized by the
NF-kB, AP-1, and IRF pathways (208).
The unique localization of this receptor in the cytoplasm leaves
many unanswered questions but simultaneously answering many.
It helps to explain how partially opsonized pathogens may still
be recognized and neutralized during the early phase of infection,
escaping recognition by the complement and FcγR system. The
relative importance of this system is still unknown during sec-
ondary infections, but may perhaps be relatively more important
at locations where complement and the myeloid system are less
prominently present, e.g., at mucosal surfaces of the gut.
DC-SIGN
The cytotoxic activity of sialylated IgG has been described to be
reduced in mice (125). Some of the immunomodulary activity
of IVIg has been attributed to binding of sialylated fraction IgG
to dendritic cell-specific ICAM-3 grabbing non-integrin (DC-
SIGN or SIGN-R1 in mice) (209, 210). Since this glycoform of
IgG represents only a small fraction (<10%) of all IgG in the
blood and IVIG treatment typically requires very high doses, it
was suggested that this fraction may be predominantly respon-
sible for the immunomodulatory functions of IVIG. However,
the precise mechanisms of this interaction are unknown, and still
await confirmation – particularly in the human setting, but also in
mice as some of the methods used to enrich IVIG for SA were
found to predominantly – if not exclusively – enrich for Fab-
associated SA (58, 59). It has been hypothesized that DC-SIGN
binds to the CH2–CH3 interface of the Fc domain of IgG, owing
to the opening up of the site, where DC-SIGN binds due to the
charged sialic acid. The simultaneous closing the interaction site
for FcγRs has then proposed to yield an anti-inflammatory IgG
(50, 124). Crosslinking of SIGN-R1 in mice has been described
to result in the release of IL-33, which in turn activates basophils
to secrete IL-4, upregulating expression of the inhibitory FcγRIIb
(209). However, recently an alternative receptor, the dendritic cell
immunoreceptor (DCIR) has been put forward as an alternative
candidate mediating the anti-inflammatory effect of silalylated-
IgG, inducing upregulation of T regulatory cells, and minimizing
Ig-complex-mediated airway hyperresponsiveness (211). To com-
plicate things even further, a recent report claims sialic acid con-
tents of IgG not to influence IgG binding to DC-SIGN, but to be
rather Fab mediated (212).
Furthermore, a number of Siglecs (Siglec-2/CD22, Siglec-8,
Siglec-9) have been implicated as ligands for IVIG (213–215),
although in case of Siglec-9, there is evidence that lectin-specific
antibodies in IVIG rather than sialylated antibodies are responsible
for binding (216).
CONCLUDING REMARKS
Immunoglobulin G-mediated responses diverge and depend
largely on the type of secondary immune responses, which in
turn depend on the type of antigen. This directs the immune
response to a specific IgG subclass or subclasses – the function
of which differs greatly between them. Besides this variation, the
IgG profile of a given individual determined by their inherited
allotypes can potentially influence the clinical manifestation of
the immune response, which ultimately differs between individu-
als and populations. An even greater level of complexity is added
by the profound variation seen in the glycosylation of the Fc tail,
affecting binding to various receptors – the nature of which we are
just beginning to understand.
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